Indeed, the EGFR tyrosine kinase inhibitors such as lapatinib and gefitinib, and the HER2/neu-targeted agent trastuzumab, have been shown to possess notable antitumor activity in several types of cancers [14]. The gene discussed is ERBB2; the disease is cancer.